British Journal of Haematology · 2003 · 73 citations · 8 references
Mixed-phenotype Acute LeukemiaImmunologyCommon AllPathologyClinical FeaturesE2a–pbx1 FusionTumor BiologyHematological MalignancyE2a-pbx1+ Adult AllOncologyHematologyCancer Cell BiologyMolecular OncologyCancer ResearchLymphoid NeoplasiaCell BiologyMolecular MedicineAdult T-cell Leukemia-lymphomaMedicineMinimal Residual Disease
Molecular and cytogenetic studies performed in 305 adult acute lymphoblastic leukaemia (ALL) patients enrolled in the gimema (Gruppo Italiano Malattie EMatologiche dell'Adulto) multicentric protocols identified an E2A-PBX1 fusion and/or t(1;19) in 10 patients (3.3%). All had common ALL, were mostly CyIg+ and were CD34/CD13/CD33-. Nine patients achieved a complete remission (CR); five patients showed a haematological relapse after 7 months (median). Four patients are alive in first CR with a median follow-up of 29 months; three patients are molecularly negative. This abnormality is frequently associated with early treatment failure. E2A-PBX1+ adult ALL should be considered for intensified treatment strategies and monitoring of minimal residual disease.
8